CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV‐2 infections.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 7, doi. 10.1002/ddr.21752
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2021 AND VI 82 AND IP 1
Results: 15
1
2
Targeting N‐acetylgalactosaminyltransferase for anticancer therapy.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 3, doi. 10.1002/ddr.21744
- By:
- Publication type:
- Article
3
Osteoarthritis: Prognosis and emerging therapeutic approach for disease management.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 49, doi. 10.1002/ddr.21741
- By:
- Publication type:
- Article
4
Combining kinase inhibitors for optimally co‐targeting cancer and drug escape by exploitation of drug target promiscuities.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 133, doi. 10.1002/ddr.21738
- By:
- Publication type:
- Article
5
Bacterial hepatocyte growth factor receptor agonist stimulates hepatocyte proliferation and accelerates liver regeneration in a partial hepatectomy rat model.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 123, doi. 10.1002/ddr.21737
- By:
- Publication type:
- Article
6
The involvement of protein TNFSF18 in promoting p‐STAT1 phosphorylation to induce coronary microcirculation disturbance in atherosclerotic mouse model.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 115, doi. 10.1002/ddr.21735
- By:
- Publication type:
- Article
7
A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 108, doi. 10.1002/ddr.21734
- By:
- Publication type:
- Article
8
Phase I safety, tolerability, and pharmacokinetic studies of tetramethylpyrazine nitrone in healthy Chinese volunteers.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 97, doi. 10.1002/ddr.21733
- By:
- Publication type:
- Article
9
Snake venom‐derived bradykinin‐potentiating peptides: A promising therapy for COVID‐19?
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 38, doi. 10.1002/ddr.21732
- By:
- Publication type:
- Article
10
Potentiality of Q3 characterization of nanosystem: Surrogate data for obtaining a biowaiver.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 27, doi. 10.1002/ddr.21731
- By:
- Publication type:
- Article
11
Epigallocatechin gallate and theaflavin gallate interaction in SARS‐CoV‐2 spike‐protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 86, doi. 10.1002/ddr.21730
- By:
- Publication type:
- Article
12
A novel series of substituted 1,2,3‐triazoles as cancer stem cell inhibitors: Synthesis and biological evaluation.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 68, doi. 10.1002/ddr.21723
- By:
- Publication type:
- Article
13
Stevioside protects against rhabdomyolysis‐induced acute kidney injury through PPAR‐γ agonism in rats.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 59, doi. 10.1002/ddr.21722
- By:
- Publication type:
- Article
14
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus‐2 disease: COVID‐19.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 12, doi. 10.1002/ddr.21720
- By:
- Publication type:
- Article
15
Issue Information.
- Published in:
- Drug Development Research, 2021, v. 82, n. 1, p. 1, doi. 10.1002/ddr.21690
- Publication type:
- Article